Connect with us

CBD News

Banks And Credit Unions Less Reluctant To Serve Cannabis Companies In Q3

Jane Summers

Published

on

Banks-Less-Reluctant-to-Serve-Cannabis-Businesses
- Ad -

The Financial Crimes Enforcement Network (FinCEN) of the U.S. Treasury Department, released new data concerning financial services to marijuana industry businesses. The report, from March 2019, shows  an increase in financial institutions serving the cannabis industry.

For example, in this report, it appears that 493 banks and 143 credit unions were willing to serve marijuana business. This is an increase from last year, in which just 411 institutions participated.

Since March 2019, another report was reportedly released. As of June 30, 553 banks and 162 credit unions showed that they submitted documents that they were serving cannabis businesses that were legal in their states. This is an increase from the previous report described above, and the one beforehand. The continued increases show that financial institutions are becoming less reluctant to provide cannabis businesses with financial resources. However, there are ongoing issues with banks serving the industry.

According to a news report by the Orlando Sentinel, “[B]ecause the U.S. federal government still classifies cannabis as a Schedule 1 drug [] any money from cannabis businesses deposited into a U.S. bank account violates the Bank Secrecy Act and can be seized.”

The question that arises here is whether the increase in the willingness of banks to serve cannabis businesses is having any effect upon the industry. Though it may have some, it still appears that the industry is underbanked and is struggling to finance its growth, according to a report CNBC. The report also indicates that most financial institutions, including banks and payment processing services such as Visa and Mastercard, refuse to work with businesses in the cannabis industry. As the news report further explains, “Although medical or recreational use of marijuana is now legal in 33 states, marijuana is still classified as a schedule 1 substance under federal law, putting it in the same category as heroin, LSD and ecstasy. Most financial institutions, such as banks, Visa and Mastercard, will not work with the cannabis industry, fearing federal prosecution.”

Therefore, even though there has been some headway, it apparently has not been enough for significant changes to take place amid ongoing federal prohibition And cannabis businesses are not the only ones that are being impacted – ancillary services, such as cleaning landlord, and consulting businesses are also challenged by the lack of finance options because of their dealings with marijuana businesses. It is impossible to know when or if things will change enough for the headway that businesses and their corresponding services experience to dissipate.

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.